MX2023011923A - Anticuerpos multiespecificos dirigidos al antigeno de maduracion de celulas b. - Google Patents

Anticuerpos multiespecificos dirigidos al antigeno de maduracion de celulas b.

Info

Publication number
MX2023011923A
MX2023011923A MX2023011923A MX2023011923A MX2023011923A MX 2023011923 A MX2023011923 A MX 2023011923A MX 2023011923 A MX2023011923 A MX 2023011923A MX 2023011923 A MX2023011923 A MX 2023011923A MX 2023011923 A MX2023011923 A MX 2023011923A
Authority
MX
Mexico
Prior art keywords
antibody targeting
specific antibody
targeting bcma
vector
bcma
Prior art date
Application number
MX2023011923A
Other languages
English (en)
Spanish (es)
Inventor
Xin Wang
Wei Zhao
Bing Zhang
Min Du
Yamin Lu
Xiuzhen Du
Zipeng Zhen
Meijuan Xie
Junxiao Xi
Xin Song
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023011923A publication Critical patent/MX2023011923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023011923A 2021-04-15 2022-04-14 Anticuerpos multiespecificos dirigidos al antigeno de maduracion de celulas b. MX2023011923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110405638 2021-04-15
PCT/CN2022/086842 WO2022218380A1 (zh) 2021-04-15 2022-04-14 靶向bcma的多特异性抗体

Publications (1)

Publication Number Publication Date
MX2023011923A true MX2023011923A (es) 2023-10-23

Family

ID=83640152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011923A MX2023011923A (es) 2021-04-15 2022-04-14 Anticuerpos multiespecificos dirigidos al antigeno de maduracion de celulas b.

Country Status (12)

Country Link
US (1) US20240182592A1 (https=)
EP (1) EP4324853A4 (https=)
JP (1) JP2024516098A (https=)
KR (1) KR20230170721A (https=)
CN (1) CN117062840A (https=)
AU (1) AU2022256638A1 (https=)
BR (1) BR112023020341A2 (https=)
CA (1) CA3214012A1 (https=)
IL (1) IL307308A (https=)
MX (1) MX2023011923A (https=)
TW (1) TW202304963A (https=)
WO (1) WO2022218380A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12612635B2 (en) 2020-08-20 2026-04-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-binding single variable structural domain and antigen-binding molecule
JP7821161B2 (ja) * 2020-08-20 2026-02-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
KR20260005269A (ko) * 2023-04-24 2026-01-09 치아타이 티안큉 파마수티컬 그룹 주식회사 c-Met를 표적으로 하는 다중 특이성 항체
CN119119246B (zh) * 2024-06-26 2025-10-10 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种抗非洲猪瘟病毒k205r蛋白的纳米抗体及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018028647A1 (en) 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
JP7267914B2 (ja) * 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
KR20250007003A (ko) * 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2019195535A1 (en) 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
JP7821161B2 (ja) * 2020-08-20 2026-02-26 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用

Also Published As

Publication number Publication date
CN117062840A (zh) 2023-11-14
IL307308A (en) 2023-11-01
TW202304963A (zh) 2023-02-01
BR112023020341A2 (pt) 2024-02-06
AU2022256638A1 (en) 2023-11-09
WO2022218380A1 (zh) 2022-10-20
EP4324853A1 (en) 2024-02-21
JP2024516098A (ja) 2024-04-12
CA3214012A1 (en) 2022-10-20
EP4324853A4 (en) 2025-07-16
KR20230170721A (ko) 2023-12-19
US20240182592A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
MX2023011923A (es) Anticuerpos multiespecificos dirigidos al antigeno de maduracion de celulas b.
MX2023009011A (es) Inhibidor de cdk.
MX2016015952A (es) Constructos de anticuerpo multiespecifico.
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CL2018003807A1 (es) Anticuerpo humanizado aislado que une al cd134 humano; molécula de ácido nucleico aislada; vector que comprende a la misma célula anfitriona que comprende al mismo; uso del anticuerpo para potenciar una respuesta inmune; uso del anticuerpo para el tratamiento del cáncer, una composición farmacéutica que comprende el anticuerpo. (divisional solicitud 201502793)
CL2020000937A1 (es) Anticuerpo multiespecífico.
AR074124A1 (es) Composiciones y metodos para inhibir la expresion de genes del factor vii
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
CL2016002116A1 (es) Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13).
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
CL2008000857A1 (es) Acido ribonucleico de doble cadena para inhibir la expresion de un gen e6ap humano en una celula; vector y celula; composicion farmaceutica que lo comprende; y su uso para tratar trastornos asociados con el virus de papiloma humano.
EA201990032A1 (ru) Способы и композиции для терапии посредством потенциирования стволовых клеток
MX2016016871A (es) Metodo para mejorar el valor nutricional de pienso para animales.
DOP2023000037A (es) Compuestos fosfolípidos y usos de los mismos
PE20160528A1 (es) Anticuerpos
DOP2023000074A (es) Compuestos fosfolípidos y usos de estos
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CL2020001821A1 (es) Formulación de adenovirus del grupo b.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
CO2019008831A2 (es) Composición química
PE20241357A1 (es) Anticuerpo biespecifico anti-cldn4/anti-cd137
MX2024015396A (es) Anticuerpo y su uso
CO2025016094A2 (es) Anticuerpo biespecífico dirigido al receptor acoplado a proteína g